Trial Profile
A phase 3 randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 [muraglitazar] in combination with metformin therapy in subjects with type 2 diabetes who have inadequate glycemic control on metformin therapy alone
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Muraglitazar (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 02 Nov 2006 Status change
- 17 Dec 2005 New trial record.